Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers.

Machine translation Machine translation
类别 Primary study
期刊Clinica chimica acta; international journal of clinical chemistry
Year 2012
指示为前列腺活检目前主要基于前列腺特异性抗原(PSA)的血清水平和数字直肠指检(DRE)。鉴于不能令人满意的精度的这两个诊断检查的,研究集中在新型标志物,以提高预活检前列腺癌检测,如披和PCA3。这项前瞻性研究的目的是评估披的诊断准确性和PCA3用活检为金标准前列腺癌。披指数(Beckman Coulter公司的免疫),PCA3比分(PROGENSA PCA3法)等地建立了生物标记物(的tPSA,游离PSA和游离PSA%),在其第一次活检18芯前列腺穿刺活检的一组受试者251之前进行了评估。%P2PSA和Phi的值均高于显著患者的前列腺癌与前列腺癌阴性组(P <0.001),也与高级别上皮内瘤(HGPIN)(P <0.001)相比。PCA3评分值均高于显著前列腺癌与前列腺癌阴性组(P <0.001),并在HGPIN VS前列腺癌阴性的患者(P <0.001)。ROC曲线分析表明%P2PSA,皮皮和PCA3是预测恶性肿瘤。总之,%P2PSA,皮皮和PCA3可以预测前列腺癌的男性接受他们的第一次前列腺穿刺活检诊断。PCA3得分是在HGPIN和非癌症区分更有用。
Epistemonikos ID: 02294f2b74e3f17ebcb826d5dc4029af6a6a8532
First added on: Apr 24, 2014
Warning
This is a machine translation from an article in Epistemonikos.

Machine translations cannot be considered reliable in order to make health decisions.

See an official translation in the following languages: English

If you prefer to see the machine translation we assume you accept our terms of use